Observational studyMedicine2025
Dynamic change of novel systemic inflammation markers in predicting perinatal outcomes after antenatal corticosteroids in preeclampsia.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessment of albumin-related inflammatory indices in preeclampsia and their relationship with composite adverse perinatal outcomes.BMC pregnancy and childbirth · 2026Article
- Oxidative Stress in Pathogenesis of Preeclampsia: Mechanistic and Clinical Insights.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is characterized by systemic inflammation and endothelial dysfunction, contributing to adverse maternal and neonatal outcomes. Antenatal corticosteroids (ACS) therapy is widely used to enhance fetal lung maturity in women at risk of preterm birth. However, little is known about the dynamic changes in maternal inflammatory markers after ACS administration in PE and their potential predictive value for perinatal outcomes. This retrospective cohort study included 206 pregnant women with PE who received ACS therapy due to preterm birth risk. Complete blood count (CBC) parameters and systemic inflammatory indices were recorded before and after ACS. Delta (Δ) values were calculated to reflect the percentage change between pre- and post-ACS measurements. Correlations between Δ inflammatory markers and perinatal outcomes were analyzed, and predictive performance was assessed using receiver operating characteristic (ROC) curve analysis. Following ACS administration, neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and aspartate aminotransferase-to-platelet ratio (APRI) increased significantly, while lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) decreased. Δ mean platelet volume (MPV), Δ aspartate aminotransferase (AST), Δ Lactate Dehydrogenase (LDH), ΔNLR, and ΔAPRI showed low-level positive correlations with umbilical cord blood pH. ROC analysis indicated that ΔMPV ≤ 1.81 (area under the curve (AUC) = 0.664) and ΔAPRI ≤ 1.81 (AUC = 0.605) moderately predicted neonatal intensive care unit (NICU) admission. Dynamic changes in maternal inflammatory markers occur after ACS therapy in preeclamptic pregnancies. ΔMPV and ΔAPRI demonstrated potential predictive value for NICU admission, highlighting their possible clinical utility in risk stratification. These findings provide novel insight into the maternal inflammatory response to ACS in PE and its implications for perinatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.